Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In patients with severe eosinophilic asthma and sputum eosinophil counts of ≥3-<30%, sputum eosinophils may not represent a more useful biomarker than blood eosinophils for predicting clinical treatment response to mepolizumab https://bit.ly/3pOTw93.

Original publication

DOI

10.1183/23120541.00560-2021

Type

Journal article

Journal

ERJ open research

Publication Date

04/2022

Volume

8

Pages

560 - 2021

Addresses

Respiratory Medicine Unit and Oxford Respiratory National Institute for Health Research Biomedical Research Centre, Nuffield Dept of Medicine, Oxford, UK.